Anti-Hypertensive Drugs Market: By Drugs Type (Diuretics, Calcium channel blockers, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor antagonists, Beta-adrenoceptor antagonists) & Geography-Forecast (2014-2021)

  • ID: 3919920
  • Report
  • 161 pages
  • IndustryARC
1 of 3
Hypertension (HTN or HT) is a long term medical condition when blood flows through the blood vessels with a force greater than normal through the arteries and is persistently elevated. High blood pressure usually does not cause symptoms. Long term high blood pressure, however, is a major risk factor for coronary artery disease, stroke, heart failure, peripheral vascular disease, vision loss, and chronic kidney disease. This is also classified as life style related disease affecting human health. Globally instances related to hypertension are constantly increasing due to various factors which include rapid urbanization, demographic ageing and the globalization of unhealthy lifestyles. This report is focused on identifying market size for anti-hypertensive drugs, drugs which are used to control hypertension. Increasing patient pool globally is one of the major drivers for the growth of the anti-hypertensive drugs coupled with increasing R&D activities and increasing approval for new drugs.

This report identifies the anti-hypertensive drugs market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to anti-hypertensive drugs market.

Globally North America is the largest market for hypertension drugs in 2015 followed by Europe and Asia-Pacific as second and third largest regional markets respectively. US is the major revenue contributor in the North American region due to fast and stressful life style of the population. North America is expected to continue dominating anti-hypertensive drugs market due to comorbid conditions among the older population like congenital heart disease and increasing focus on combination therapies will prevent the decline in the market. However anti-hypertensive market in Asia-Pacific region is expected to grow fastest due to increasing demand of anti-hypertensive drugs in the region due to changing life style of the people in the region.

On the basis of anti-hypertensive drug type this report classifies as follows covering all major types of drugs available in the market: Diuretics, Calcium channel blockers, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor antagonists, Beta-adrenoceptor antagonists and Others
This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for anti-hypertensive drugs in each of the region.

This report identifies all the major companies operating in the global anti-hypertensive drugs market. Some of the major companies’ profiles in detail are as follows:

Pfizer Inc.
Sanofi S.A
Johnson & Johnson Ltd.
Daiichi - Sankyo
Merck & Co.
Ranbaxy Laboratories Limited
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 3
1. Anti-Hypertensive Drugs - Market Overview
2. Executive Summary
3. Anti-Hypertensive Drugs Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis
4. Anti-Hypertensive Drugs - Market Forces
4.1. Drivers
4.1.1. Increasing number of patients with hypertension globally
4.2. Restraints
4.2.1. Possible side effects over a long term
4.3. Opportunities
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Anti-Hypertensive Drugs - Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. Global Anti-Hypertensive Drugs Market, By Drugs Type (2014-2021)
6.1. Diuretics
6.2. Calcium channel blockers
6.3. Angiotensin-converting enzyme (ACE) inhibitors
6.4. Angiotensin II receptor antagonists
6.5. Beta-adrenoceptor antagonists
6.6. Others
7. Global Anti-Hypertensive Drugs Market, By Geography (2014-2021)
7.1. Europe
7.1.1. Germany
7.1.2. France
7.1.3. Italy
7.1.4. Spain
7.1.5. Russia
7.1.6. U.K.
7.1.7. Rest of Europe
7.2. Asia Pacific
7.2.1. China
7.2.2. India
7.2.3. Japan
7.2.4. South Korea
7.2.5. Rest of Asia-Pacific
7.3. North America
7.3.1. U.S.
7.3.2. Canada
7.3.3. Mexico
7.4. Rest of the World (RoW)
7.4.1. Brazil
7.4.2. Rest of RoW
8. Anti-Hypertensive Drugs - Market Entropy
8.1. Expansion
8.2. Technological Developments
8.3. Merger & Acquisitions, and Joint Ventures
8.4. Supply - Contract
9. Company Profiles (Top 10 Companies)
9.1. Novartis AG
9.1.1. Introduction
9.1.2. Financials
9.1.3. Key Insights
9.1.4. Key Strategy
9.1.5. Product Portfolio
9.1.6. SWOT Analysis
9.2. Pfizer Inc.
9.2.1. Introduction
9.2.2. Financials
9.2.3. Key Insights
9.2.4. Key Strategy
9.2.5. Product Portfolio
9.2.6. SWOT Analysis
9.3. Sanofi S.A
9.3.1. Introduction
9.3.2. Financials
9.3.3. Key Insights
9.3.4. Key Strategy
9.3.5. Product Portfolio
9.3.6. SWOT Analysis
9.4. Johnson & Johnson Ltd.
9.4.1. Introduction
9.4.2. Financials
9.4.3. Key Insights
9.4.4. Key Strategy
9.4.5. Product Portfolio
9.4.6. SWOT Analysis
9.5. Daiichi - Sankyo
9.5.1. Introduction
9.5.2. Financials
9.5.3. Key Insights
9.5.4. Key Strategy
9.5.5. Product Portfolio
9.5.6. SWOT Analysis
9.6. Merck & Co.
9.6.1. Introduction
9.6.2. Financials
9.6.3. Key Insights
9.6.4. Key Strategy
9.6.5. Product Portfolio
9.6.6. SWOT Analysis
9.7. Ranbaxy Laboratories Limited
9.7.1. Introduction
9.7.2. Financials
9.7.3. Key Insights
9.7.4. Key Strategy
9.7.5. Product Portfolio
9.7.6. SWOT Analysis
9.8. Lupin Limited
9.8.1. Introduction
9.8.2. Financials
9.8.3. Key Insights
9.8.4. Key Strategy
9.8.5. Product Portfolio
9.8.6. SWOT Analysis
9.9. AstraZeneca Plc.
9.9.1. Introduction
9.9.2. Financials
9.9.3. Key Insights
9.9.4. Key Strategy
9.9.5. Product Portfolio
9.9.6. SWOT Analysis
9.10. Dr. Reddy’s Laboratories
9.10.1. Introduction
9.10.2. Financials
9.10.3. Key Insights
9.10.4. Key Strategy
9.10.5. Product Portfolio
9.10.6. SWOT Analysis

"*Financials would be provided on a best efforts basis for private companies"
10. Appendix
10.1. Abbreviations
10.2. Sources
10.3. Research Methodology
10.4. Expert Insights
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown